Sign up to save your podcasts
Or
Share Innovations in Psychedelic Therapeutics and Pain Management at the Milken Conference
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Innovations in Psychedelic Therapeutics and Pain Management at the Milken Conference
Cybin Inc. CEO Doug Drysdale will discuss drug development innovation and next-generation mental health treatments at the Milken Institute Global Conference. Meanwhile, Silo Pharma Inc. has reported positive preclinical data for its SP-26 Ketamine Implant for fibromyalgia and filed a patent application for SPC-14 targeting cognitive and neuropsychiatric symptoms in Alzheimer’s disease, showcasing advancements in pain management and cognitive health therapeutics.
View all episodes
Cybin Inc. CEO Doug Drysdale will discuss drug development innovation and next-generation mental health treatments at the Milken Institute Global Conference. Meanwhile, Silo Pharma Inc. has reported positive preclinical data for its SP-26 Ketamine Implant for fibromyalgia and filed a patent application for SPC-14 targeting cognitive and neuropsychiatric symptoms in Alzheimer’s disease, showcasing advancements in pain management and cognitive health therapeutics.